6-K
Zhongchao Inc. (ZCMD)
UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2020
ZHONGCHAO INC.
(Translation of Registrant's name into English)
Nanxi Creative Center, Suite 218
841 Yan’an Middle Road
Jing’An District, Shanghai, China 200040
Tel: 021-32205987
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
CONTENTS
On August 4, 2020, Zhongchao Inc. (the “Company”) issued a press release announcing the renewal of contract with Johnson & Johnson (China) Limited (“J&J”), pursuant to which the Company shall continue to serve as J&J’s vendor and partner in China, extending the long-standing cooperation between the Company and J&J in medical research, medical training and education, and brand building since 2017.
A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Financial Statements and Exhibits.
| Exhibit | Description |
|---|---|
| 99.1 | Press release dated August 4, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Zhongchao Inc. | |
|---|---|
| By: | /s/ Weiguang Yang |
| Name: | Weiguang Yang<br><br> <br>Chief Executive Officer |
| Title: |
Date: August 4, 2020
Exhibit 99.1
****
Zhongchao Inc. Renews Contract with Johnson& Johnson (China) Limited, Extending the Cooperation since 2017
Shanghai, China, Aug. 4, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced the renewal of contract with Johnson & Johnson (China) Limited (“J&J”), pursuant to which the Company shall continue to serve as J&J’s vendor and partner in China, extending the long-standing cooperation between the Company and J&J in medical research, medical training and education, and brand building since 2017.
“As a Fortune Global 500 company and the largest pharma company in world measured by 2019 revenue (Fierce Pharma, April 2020), J&J has a strong presence in the Chinese market with multiple R&D centers and manufacturing facilities and has developed and introduced a large number of medical devices, pharmaceutical products and technologies (together, the “Products and Technologies”) in the Chinese markets. For example, during the 21 months ended October 2019, Xi’An Janssen, a majority owned subsidiary of J&J, was granted approval of over 22 new drugs or indications in China, covering psychiatry, hematology, solid tumors, immunology, infectious diseases, diabetes, and pulmonary hypertension, etc. The marketing and promotions of these newly introduced Products and Technologies create significant opportunities for vendors like Zhongchao,” commented Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao.
“We see the Chinese healthcare market remains in its early stage of development and believe it still has tremendous growth trajectory ahead of it. Through cooperation and partnership with leading pharmaceutical companies like J&J, Zhongchao is poised to capture its fair share of the growth in years to come,” concluded Mr. Yang.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online provider of healthcare information, professional training and educational services to healthcare professionals under its “MDMOOC” platform (www.mdmooc.org) and to the public under its “Sunshine Health Forums” platform (www.ygjkclass.com) in China. More information about the Company can be found at its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-lookingstatements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerningplans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are otherthan statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,”“believe,” “expect,” “anticipate,” “project,” “estimate” or similarexpressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statementsare not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materiallyfrom the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties andrisks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development;product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional trainingand educational services market in China and the other international markets the Company plans to serve; reputation and brand;the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Chinaand the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and otherrisks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, includingits impacts across our business and operations. For these reasons, among others, investors are cautioned not to place unduereliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filingswith the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-lookingstatements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations:
Tony Tian, CFA
Weitian Group LLC
Email: ttian@weitianco.com
Phone: +1 732-910-9692